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Large	Islets,	Beta-Cell	Proliferation,		
and	a	Glucokinase	Mutation
To the Editor: Rare, naturally occurring gene 
mutations provide important insights into nor-
mal human physiology. We report on a young girl 
with severe neonatal hypoglycemia due to a novel 
glucokinase mutation (V91L). Her father had a 
similar clinical course, but neither his DNA nor 
his pancreatic tissue was available for study. 
V91L showed a markedly increased affinity for 
glucose that was more than 8.5 times as high, an 
enzyme efficiency that was 7 times as high, and 
a relative-activity index that was 30 times as high 
as that of the wild-type enzyme. The estimated 
threshold for glucose-stimulated insulin secretion 
was markedly lower than that of the wild-type 
enzyme (0.96 vs. 5.00 mmol per liter). Diazoxide 
and octreotide therapy did not control the pa-
tient’s hypoglycemia, and a subtotal pancreatecto-
my was performed when she was 3 years of age. 
Quantitative histologic examination revealed 
abnormally large islets (Fig. 1A) with some beta 
cells containing a large nucleus (Fig. 1C). The 
mean islet area was 7705 μm2 in the head of the 
pancreas and 7048 μm2 in the tail of the pan-
creas. Both areas were significantly larger than 
those in specimens obtained from five age-matched 
control subjects who did not have pancreatic dis-
ease (range, 1160 to 1997 μm2; P<0.001) and in 
three specimens obtained from two age-matched 
subjects with diffuse hypoglycemia due to ABCC8 
gene mutations (ATP-sensitive potassium-chan-
nel [KATP ]–related hypoglycemia) (range, 769 to 
859 μm2; P<0.001). All these subjects were in 
subgroups of a population from a previously pub-
lished study.1 Approximately 10% of the patient’s 
islets were larger than 13,000 μm2; this was 
generally larger than any islet in the pancreases 
of control subjects or subjects with KATP-related 
hypoglycemia. The relative beta-cell area (the per-
centage of the histologic section that stained posi-
tive for insulin) was 2.9% in the head of the pan-
creas and 6.7% in the tail of the pancreas in the 
patient, as compared with 1.8% in the pancreases 
of the control subjects and 1.1% in the pancre-
ases of the subjects with KATP-related hypoglyce-
mia. In the patient’s pancreas, nine proliferating 
(Ki67-positive) beta cells were detected in 100 is-
lets (Fig. 1E) and apoptotic (terminal deoxynucleo-
tidyl transferase dUTP biotin nick end labeling 
[TUNEL]-positive) beta cells were observed clus-
tering within some islets (Fig. 1G). Neither Ki67-
positive nor TUNEL-positive cells were seen in 
Figure	1	(facing	page).	Histologic	Features	of	the	Pan-
creas	in	the	Patient	and	in	Age-Matched	Control	Sub-
jects	with	Normal	Pancreases.
Panel A (hematoxylin and eosin) shows a large islet 
(dotted line) near blood vessels (BV) in a biopsy speci-
men obtained from the patient, and Panel B (hematox-
ylin and eosin) shows a normal-size islet (dotted line) 
in a specimen obtained from a control subject; both 
Panel A and Panel B are specimens shown at low magni-
fication. Panel C shows abnormally large beta-cell nuclei 
(arrows) in the patient’s specimen at higher magnifica-
tion than in Panel A, and Panel D shows  beta-cell nuclei 
in a control subject’s specimen at the same magnifica-
tion. Panel E (Cy5) shows Ki67-positive beta cells (reddish-
purple nuclei, arrows) in a large islet in a specimen ob-
tained from the patient; Panel F shows beta cells in a 
specimen obtained from a control subject. In Panels E 
and F, Cy2-labeled insulin shows green cytoplasmic stain-
ing. Panel G shows terminal deoxynucleotidyl transferase 
dUTP biotin nick end labeling–positive cells (green nu-
clei, arrows) in the patient’s specimen; these cells were 
not detected in any of the specimens obtained from con-
trol subjects (a specimen from one control subject is 
shown in Panel H). In Panels G and H, Cy5-labeled insu-
lin shows red cytoplasmic staining.
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any of the pancreases of the control subjects 
(Fig. 1F and 1H), suggesting that increased intra-
cellular glucose flux stimulates both proliferation 
and apoptosis pathways.
Normal histologic findings in four previous 
cases of glucokinase-related hypoglycemia have 
been reported, but none of these patients under-
went detailed quantitative morphometric analy-
sis.2‑4 In a previously reported case that included 
quantitative histologic analysis, a similar increase 
in the mean islet profile was confirmed (it was 
2.5 times larger than that of control subjects and 
8.0 to 10.0 times larger than that of patients with 
a KATP-channel deficiency).5 In both that patient 
and our patient, the routine pathology report did 
not indicate any abnormality in islet size; this 
emphasizes the importance of quantitative mor-
phometric analysis to determine islet size.
Thus, histologic findings in infants with hy-
perinsulinemic hypoglycemia may differ accord-
ing to the genetic cause of the condition. Further-
more, intracellular glucose flux appears to regulate 
proliferation and apoptosis in human beta cells; 
this is consistent with previous findings in mu-
rine models. Small-molecule activators of glu-
cokinase are currently being developed for the 
clinical management of diabetes. Although ob-
servations in this young child with a congenital 
glucokinase mutation may not be directly appli-
cable to adults with diabetes, the effect of these 
glucokinase activators on human beta-cell mass 
may be of interest.
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Sudden Death in Myotonic Dystrophy (October 9, 2008;359: 
1626-9). In Panel B of Figure 1 (page 1627), under the Controls 
heading, the value for N should have been 14 rather than 7. We 
regret the error. The article has been corrected at NEJM.org.
Case 13-2009: A 54-Year-Old Woman with Respiratory Failure 
and a Cavitary Lesion in the Lung (April 23, 2009;360:1770-9). In 
the fourth sentence of the Summary subsection under Differen-
tial Diagnosis (pages 1776-7), the phrase “receive pneumococcal 
and influenza vaccines annually” should have read “receive 
pneumococcal vaccines every 5 years and influenza vaccines an-
nually.” The article has been corrected at NEJM.org.
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